TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07228442: A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment

Sponsor: Philogen S.p.A. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 92 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$5,636,400

Rescue Site Savings

+$3,742,200

Unlock Full NCT07228442 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07228442 Rescue Dossier →